

Niagen Bioscience, Inc. (NAGE)

Nasdaq; healthcare; SIC 2833, Medicinal Chemicals & Botanical Products; CIK 0001386570

Niagen Bioscience, Inc. NAGE; healthcare		
Grade	A ▼ A B C D E strongest fifth of 371 graded peers percentile 10.8; sampling error 2.5 points; lower is stronger	
Rank	41 of 371	
Profitability	B/C percentile 41.7	
Solvency	B percentile 31.3	
Growth and financing	B percentile 28.4	
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$106.4M	
Standard universe	inside revenue above \$1M and assets above \$10M	
Warnings	none active not computable: short runway, distress, fortress balance sheet	
Inputs computable	8 of 14	
Graded from	filings received through Mar 4, 2026 219 days before the rescans; latest periodic filing 10-Q received Aug 4, 2026	
Last close	\$2.65 2026-10-08; market equity \$210.1M	
Price used in grade	None	




A, the bull

strongest fifth of its sector;
letters are fifths of the 371 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: A/B from Nov 21, 2024, B from Dec 21, 2024, A/B from Jan 21, 2025

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 4, 2026

Unless otherwise indicated or the context otherwise requires, references to the Company, Niagen Bioscience, we, us and our refer to Niagen Bioscience, Inc. and its consolidated subsidiaries. On May 21, 2008, Cody Resources, Inc., a Nevada corporation and a public company, (Cody) entered into an Agreement and Plan of Merger (Merger Agreement), by and among Cody, CDI Acquisition, Inc., a

California corporation and wholly-owned subsidiary of Cody (Acquisition Sub), and ChromaDex, Inc. (Merger). Subsequent to the signing of the Merger Agreement, Cody merged with and into a Delaware corporation.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 41.7						
Gross profitability		78.2%	32.2%	10.5	372	2025-12-31
Return on invested capital		not computable	9.3%			required facts have no common fiscal period end
Accruals ratio		4.4%	(6.6%)	87.7	811	2025-12-31
Gross margin stability, five years		1.6 pts	2.8 pts	26.9	243	2025-12-31
Solvency, sleeve percentile 31.3						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		3.42	(0.31)	24.2	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			required facts have no common fiscal period end
Interest coverage		not computable	(4.51x)			interest expense must exceed \$100,000
Current ratio		4.86x	2.96x	38.3	839	2025-12-31
Growth and financing, sleeve percentile 28.4						
Revenue growth, three-year compound		21.6%	10.0%	29.7	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		25.3%	2.1%	17.6	704	2025-12-31
Net share issuance, one year		3.0%	2.5%	37.9	634	2026-03-03

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
36	Xtant Medical Holdings, Inc. (XTNT)	9.5	A	fortress balance sheet
37	Viemed Healthcare, Inc. (VMD)	9.7	A	
38	LivaNova plc (LIVN)	10.0	A	fortress balance sheet
39	TransMedics Group, Inc. (TMDX)	10.3	A	
40	TG Therapeutics, Inc. (TGTX)	10.5	A	
41	Niagen Bioscience, Inc. (NAGE) <	10.8	A	
42	BridgeBio Pharma, Inc. (BBIO)	11.1	A	
43	PRO DEX Inc. (PDEX)	11.4	A	
44	Sanara MedTech Inc. (SMTI)	11.6	A	
45	Orthopediatrics Corp. (KIDS)	11.9	A	
46	Idexx Laboratories Inc. (IDXX)	12.2	A	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(66.5%)	8.0%	8
Distance from 52-week high	(65.0%)	(31.4%)	14
EBIT to enterprise value	10.8%	(1.5%)	92
Free cash flow yield	(10.1%)	(1.0%)	30
Book value to price	0.39	0.28	60
Sales to price	0.61	0.31	72
Composite equity issuance, five years	17.0%	20.3%	47
Relative strength against the sector, log excess return	(1.30)	(0.14)	8

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	66 (10-Q received Aug 4, 2026)

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$83.2M	2025-12-31	2026-03-04	10-K	0001386570-26-000013
2	assets	us-gaap:Assets	\$106.4M	2025-12-31	2026-03-04	10-K	0001386570-26-000013
3	net income	us-gaap:NetIncomeLoss	\$17.4M	2025-12-31	2026-03-04	10-K	0001386570-26-000013
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$13.5M	2025-12-31	2026-03-04	10-K	0001386570-26-000013
5	assets	us-gaap:Assets	\$68.3M	2024-12-31	2026-03-04	10-K	0001386570-26-000013
6	revenue	us-gaap:Revenues	\$129.4M	2025-12-31	2026-03-04	10-K	0001386570-26-000013
7	gross profit	us-gaap:GrossProfit	\$61.6M	2024-12-31	2026-03-04	10-K	0001386570-26-000013
8	revenue	us-gaap:Revenues	\$99.6M	2024-12-31	2026-03-04	10-K	0001386570-26-000013
9	gross profit	us-gaap:GrossProfit	\$50.8M	2023-12-31	2025-03-04	10-K	0001628280-25-009774
10	revenue	us-gaap:Revenues	\$83.6M	2023-12-31	2025-03-04	10-K	0001628280-25-009774
11	gross profit	us-gaap:GrossProfit	\$42.8M	2022-12-31	2024-03-06	10-K	0001628280-24-009380
12	revenue	us-gaap:Revenues	\$72.0M	2022-12-31	2024-03-06	10-K	0001628280-24-009380
13	gross profit	us-gaap:GrossProfit	\$41.5M	2021-12-31	2023-03-08	10-K	0001628280-23-006968
14	revenue	us-gaap:Revenues	\$67.4M	2021-12-31	2023-03-08	10-K	0001628280-23-006968
15	current assets	us-gaap:AssetsCurrent	\$96.8M	2025-12-31	2026-03-04	10-K	0001386570-26-000013
16	current liabilities	us-gaap:LiabilitiesCurrent	\$19.9M	2025-12-31	2026-03-04	10-K	0001386570-26-000013
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$164.5M	2025-12-31	2026-03-04	10-K	0001386570-26-000013
18	operating income	us-gaap:OperatingIncomeLoss	\$16.3M	2025-12-31	2026-03-04	10-K	0001386570-26-000013
19	book equity	us-gaap:StockholdersEquity	\$76.5M	2025-12-31	2026-03-04	10-K	0001386570-26-000013
20	liabilities	us-gaap:Liabilities	\$29.9M	2025-12-31	2026-03-04	10-K	0001386570-26-000013
21	operating income	us-gaap:OperatingIncomeLoss	-\$27.1M	2021-12-31	2023-03-08	10-K	0001628280-23-006968
22	interest expense	us-gaap:InterestExpense	\$55,000	2021-12-31	2022-03-14	10-K	0001628280-22-006041
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$20.4M	2019-12-31	2021-03-12	10-K	0001654954-21-002692
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$743,000	2019-12-31	2020-03-10	10-K	0001654954-20-002437
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$20.9M	2018-12-31	2020-03-10	10-K	0001654954-20-002437
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.3M	2018-12-31	2020-03-10	10-K	0001654954-20-002437
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$9.8M	2017-12-30	2019-03-07	10-K	0001654954-19-002395
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.2M	2017-12-30	2019-03-07	10-K	0001654954-19-002395
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$2.9M	2016-12-31	2018-03-15	10-K	0001654954-18-002621
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.5M	2016-12-31	2018-03-15	10-K	0001654954-18-002621
31	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$510,000	2017-12-30	2019-03-07	10-K	0001654954-19-002395
32	operating income	us-gaap:OperatingIncomeLoss	-\$16.4M	2017-12-30	2019-03-07	10-K	0001654954-19-002395
33	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNetIncome	\$16.5M	2017-12-30	2018-03-15	10-K	0001654954-18-002621
34	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2017-12-30	2018-03-15	10-K	0001654954-18-002621
35	current assets	us-gaap:AssetsCurrent	\$57.2M	2017-12-30	2019-03-07	10-K	0001654954-19-002395
36	current liabilities	us-gaap:LiabilitiesCurrent	\$8.1M	2017-12-30	2019-03-07	10-K	0001654954-19-002395
37	current assets	us-gaap:AssetsCurrent	\$15.7M	2016-12-31	2018-03-15	10-K	0001654954-18-002621
38	current liabilities	us-gaap:LiabilitiesCurrent	\$8.9M	2016-12-31	2018-03-15	10-K	0001654954-18-002621
39	assets	us-gaap:Assets	\$55.0M	2023-12-31	2025-03-04	10-K	0001628280-25-009774
40	assets	us-gaap:Assets	\$54.1M	2022-12-31	2024-03-06	10-K	0001628280-24-009380
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	80,080,488	2026-03-03	2026-03-04	10-K	0001386570-26-000013
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	77,750,447	2025-03-03	2025-03-04	10-K	0001628280-25-009774